Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Gynecology | Internal Medicine | Emergency Medicine | Nursing | Pharmacy | Journal

Back to Journal Articles

Blood Clot Risk Elevated in Patch and Vaginal Ring Users

Last Updated: May 11, 2012.

 

Risk of venous thrombosis higher in non-oral contraceptives compared to oral contraceptives

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Compared to nonusers of hormonal contraception, women who use combined contraceptive transdermal patches are at an eight-fold increased risk of venous thrombosis, and vaginal ring users are at a more than six-fold increased risk, according to a study published online May 10 in BMJ.

FRIDAY, May 11 (HealthDay News) -- Compared to nonusers of hormonal contraception, women who use combined contraceptive transdermal patches are at an eight-fold increased risk of venous thrombosis, and vaginal ring users are at a more than six-fold increased risk, according to a study published online May 10 in BMJ.

Øjvind Lidegaard, M.D., from the University of Copenhagen in Denmark, and colleagues analyzed data from four national registries on 1,626,158 non-pregnant Danish women, aged 15 to 49 years, who were free of previous cancer or thrombotic disease.

The researchers found that, over the nine-year study period, there were 3,434 confirmed first-ever venous thrombosis events. The incidence rate of confirmed events was 2.1 per 10,000 woman years in nonusers of hormonal contraception. After adjusting for other variables, the relative risk of confirmed venous thrombosis was 7.9 (95 percent confidence interval [CI], 3.5 to 17.7) in users of transdermal combined contraceptive patches and 6.5 (95 percent CI, 4.7 to 8.9) in users of the vaginal ring, compared to nonusers. There was also increased relative risk in women who used subcutaneous implants (1.4; 95 percent CI, 0.6 to 3.4), but not in those who used the levonorgestrel intrauterine system (0.6; 95 percent CI, 0.4 to 0.8). Compared to users of combined oral contraceptives containing levonorgestrel, the adjusted relative risk of venous thrombosis in transdermal patch and vaginal ring users was 2.3 (95 percent CI, 1.0 to 5.2) and 1.9 (95 percent CI, 1.3 to 2.7), respectively.

"Women who use transdermal patches or vaginal rings for contraception have a 7.9 and 6.5 times increased risk of confirmed venous thrombosis compared with nonusers of hormonal contraception of the same age," the authors conclude.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text

Copyright © 2012 HealthDay. All rights reserved.


Previous: Elective Induction of Labor Tied to Reduced Perinatal Mortality Next: New Technique Removes Inoperable Abdominal Tumors

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.